In recent years, immune checkpoint proteins in the tumor microenvironment have been under intense study. If you work in the immuno-oncology field, chances are you are either performing multiplex IHC (mIHC) or would like to. Ultimately, a multiplexed image like the one featured here provides a multi-layered depiction of a tumor, such that each antibody corresponds to a different fluorescent signal. If you want to detect more targets in your IHC, but aren’t sure how to design a panel of antibodies and fluorophores for mIHC, we’ll walk you through the process in this post.
Earlier this week, Dr. James Allison and Dr. Tasuku Honjo were announced as joint winners of the 2018 Nobel Prize in Physiology or Medicine for their work in the field of immunotherapy and checkpoint immune regulation. Their studies have sparked decades of clinical advances, and changed the future of cancer therapy. A webinar presented by Dr. Allison in conjunction with Dr. Gordon Freeman and Dr. Philip Gotwals is featured in this week's blog post.
Research trends in macrophage plasticity
It’s an exciting time for immuno-oncology research, as potential predictive biomarkers from an expanding collection of cell types are being pursued. Explore the plasticity of tumor-associated macrophages (TAMs) and challenges in distinguishing M1- versus M2- functional states in this 5-minute video featuring CST Developmental Scientist Sarah Klein, PhD.
Can't see the embedded video? Click here to watch.
Cell Signaling Technology is proud to partner with the Koch Institute at MIT, Science, and Science Signaling to present the Targeting Cancer Pathways webinar series. These webinars will bring together thought leaders from around the world to share current findings and further cancer research community collaboration.
The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments that harness the body’s immune system to fight cancer have transitioned from speculation to offering endless possibilities for drug discovery. Of these treatments, therapeutic monoclonal antibodies are positioned at the forefront of the immunotherapy revolution, and the FDA has approved several of these monoclonal antibodies to treat cancer.
We as scientists learn from each success and failure. Sometimes it takes many failures to achieve success. And some discoveries are made with no fanfare, far from the spotlight. Other times, a good day’s work is even sweeter when you realize someone noticed!
Cell Signaling Technology is proud to partner with the Koch Institute at MIT, Science, and Science Signaling to present the Targeting Cancer Pathways webinar series. These webinars bring together thought leaders from around the world to share current findings and further cancer research community collaboration.
This two part webinar features Dr. Li Huei Tsai from the Picower Institute at MIT and CST Development Scientist, Dr. Raphael Rozenfeld. Dr. Tsai discusses how modeling systems can be combined with immunolabeling and imaging techniques to unlock the mystery of Alzheimer's Disease. Dr Rozenfeld describes the rigorous validation procedure our antibodies undergo before being release, with special emphasis placed on our neuroscience portfolio. Check out the abstracts below and then click on the button to watch their exciting presentations.
Topics: Cancer Research
Journal Club: YAP-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer.
The article we have chosen was published in the October 29th, 2015 issue of the journal Nature by Gregorieff et al., from the Lunenfeld Tanenbaum Research Institute and University of Toronto, Ontario Canada. The article is entitled YAP-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer, and focuses on stem cell dynamics within the intestinal epithelium, the most rapidly self-renewing tissue in adult mammals.
Cell Signaling Technology is proud to present the following On-Demand Webinar:
The Use of Highly Validated Antibodies and Optimized ChIP Assays to Analyze Epigenetic Marks and Mechanism in DIsease
Sayura Aoyagi, Ph.D, CST Antibody Validation Scientist